Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.41 |
| ▸ | FABP6 | P51161 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154978 | 0.79 | ALDH1A1 (0.42) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL4716261 | 0.79 | ALDH1A1 (0.42) | MEN1LMNAMAPTMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL11018810 | 0.77 | ALDH1A1 (0.41) | MEN1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL11356667 | 0.73 | MAPT (0.38) | NPC1LMNAMAPTMAPK1RAB9A | |
| SCHEMBL8619688 | 0.73 | USP2 (0.45) | NISCHMEN1NPC1LMNAMAPT | |
| SCHEMBL10864873 | 0.72 | SLC6A2 (0.34) | — | |
| SCHEMBL8622496 | 0.72 | — | — | |
| SCHEMBL5898334 | 0.71 | NISCH (0.41) | NISCHMEN1NPC1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL11016978 | 0.71 | CYP3A4 (0.41) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL11370552 | 0.70 | ALDH1A1 (0.47) | NPC1LMNAPOLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | claimed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
| EP-0035393-A1 | Poultry feeds containing and methods of using anovulatory compounds, and novel anovulatory imidazolines | MERCK & CO. INC. (US) | 1981-09-09 | — | — | EP | disclosed |
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | NISCH 492/4885FABP6 503/4885PARP1 3250/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | NISCH 457/4885FABP6 543/4885PARP1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.